newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

  • Cogent Biosciences, Inc. has commenced underwritten public offerings of $200 million in convertible senior notes due 2031 & $200 million in common stock.
  • Underwriters have a 30-day option to purchase up to an additional $30 million in notes & $30 million in common stock to cover over-allotments.
  • The closing of the convertible notes offering is not conditioned on the closing of the equity offering.
  • The convertible notes will be general, unsecured, senior obligations maturing on November 15, 2031, with interest payable semi-annually.
  • Upon conversion, Cogent may pay or deliver cash, shares, or a combination of both at its election.
  • Net proceeds will be used to repay $50 million of outstanding term loans, plus accrued interest & fees, with the remainder allocated to development, regulatory activities, commercialization of bezuclastinib, working capital, & general corporate purposes.
  • Jefferies & J.P. Morgan are joint book-running managers for the convertible notes offering.
  • J.P. Morgan, Jefferies, Leerink Partners, & Guggenheim Securities are joint book-running managers for the equity offering, with LifeSci Capital as lead manager & Raymond James as co-manager.
  • The securities are offered pursuant to an automatic shelf registration statement on Form S-3ASR filed with the SEC on November 7, 2025.
  • Final terms of the offerings will be disclosed in final prospectus supplements filed with the SEC.